The importance of renin-angiotensin blockade in patients with cardio-renal disease

Journal of Renal Care

Volumn 36, Issue SUPPL. 1, 2010, Pages 97-105

  Benavente, David ^a   Chue, Colin D ^b   Ferro, Charles J ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cardiovascular disease; Kidney disease; Renin angiotensin aldosterone system

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DRUG EFFECT; HUMAN; MORTALITY; NURSING; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; SURVIVAL RATE;

EID: 77952559661     PISSN: 17556678     EISSN: 17556686     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2010.00166.x     Document Type: Article

References (108)

1. Agardh C.D., Garcia-Puig J., Charbonnel B. et al 1996). Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. Journal of Human Hypertension 10, 185 192.
2. Ahmad J., Siddiqui M.A., Ahmad H. (1997). Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20, 1576 1581.
3. Ahmed A.K., Kamath N.S., El Kossi M. et al 2009). The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrology Dialysis Transplantation, in press. Epublished ahead of print October 2009.
4. Allikmets K. (2007). Aliskiren - an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension. Vascular Health and Risk Management 3, 809 815.
5. Antonaccio M.J. (1982). Inhibitors of the renin-angiotensin system as new antihypertensive agents. Clinical and Experimental Hypertension A 4, 27 46.
6. Atlas S.A. (2007). The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. Journal of Managed Care Pharmacy 13, 9 20.
7. Auchus R.J. (2003). Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. Current Opinion in Nephrology and Hypertension 12, 153 158.
8. Bomback A.S., Klemmer P.J. (2007). The incidence and implications of aldosterone breakthrough. Nature Clinical Practice Nephrology 3, 486 492.
9. Booth R.E., Johnson J.P., Stockand J.D. (2002). Aldosterone. Advances in Physiology Education 26, 8 20.
10. Braun-Menendez E. Fasciolo J.C. (1939). La sustancia hipertensora de la sangre del rifion isquemiado. Revista de la Sociedad Argentina de Biologia 15, 420 425.
11. Braun-Menendez E., Page I.H. (1958). Suggested revision of nomenclature - Angiotensin. Science 127, 242.
12. Brenner B.M., Cooper M.E., de Zeeuw D. et al 2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 345, 861 869.
13. Bright P. (1983). Dr Richard Bright, pp. 1789 1858.
14. Brown-Sequard C, d'Arsonnval A 1892). Des injections sous-cutanees ou intraveineuses d'extraits liquides de nombre d'organes, comme methode therapeutique. Comptes rendus de l'Académie des sciences 64, 1399 1404.
15. Burns K.D. (2007). The emerging role of angiotensin-converting enzyme-2 in the kidney. Current Opinion in Nephrology and Hypertension 16, 116 121.
16. Cachofeiro V, Miana M., de Las Heras N. et al. (2008). Aldosterone and the vascular system. The Journal of Steroid Biochemistry and Molecular Biology 109, 331 335.
17. Cameron J.S. Hicks J. (1996). Frederick Akbar Mahomed and his role in the description of hypertension at Guy's Hospital. Kidney International 49, 1488 1506.
18. Campbell D.J. (2008). Critical review of prorenin and (pro)renin receptor research. Hypertension 51, 1259 1264.
19. Carey R.M. Siragy H.M. (2003). Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocrine Reviews 24, 261 271.
20. Casas J.P, Chua W., Loukogeorgakis S. et al 2005). Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366, 2026 2033.
21. Chiu AT., McCall D.E., Price W.A. et al 1990). Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. Journal of Pharmacology and Experimental Therapeutics 252, 711 718.
22. Conn J.W. (1955). Primary aldosteronism. Journal of Laboratory and Clinical Medicine 45, 661 664.
23. Connell J.M., MacKenzie S.M., Freel E.M. et al 2008). A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocrine Reviews 29, 133 154.
24. CONSENSUS Trial Study Group (1987). Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. New England Journal of Medicine 316, 1429 1435.
25. Curtiss C, Cohn J.N., Vrobel T. et al 1978). Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 58, 763 770.
26. Dagenais G.R., Pogue J., Fox K. et al 2006). Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368, 581 588.
27. Danser A.H., Van Den Dorpel M.A., Deinum J. et al 1989). Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. Journal of Clinical Endocrinology and Metabolism 68, 160 167.
28. de Zeeuw D., Remuzzi G., Parving H.H. et al 2004). Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney International 65, 2309 2320. (Pubitemid 38670018)
29. Delyani J.A., Rocha R., Cook C.S. et al 2001). Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovascular Drug Review 19, 185 200.
30. DiBianco R. (1986). Adverse reactions with angiotensin converting enzyme (ACE) inhibitors. Medical Toxicology 1, 122 141.
31. Edwards N.C., Steeds R.P., Stewart P.M. et al 2009). Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. Journal of the American College of Cardiology 54, 505 512.
32. Erley CM., Haefele U., Heyne N. et al 1993). Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. Hypertension 21, 810 815.
33. Farrelly R.O., Howie R.N., North J.D. (1960). Use of spironolactone and hydrochlorothiazide in treatment of oedema. British Medical Journal 2, 339 343.
34. Ferguson R.K., Vlasses PH., Irvin J.D. et al 1982). A comparative pilot study of enalapril, a new converting enzyme inhibitor, and hydrochlorothiazide in essential hypertension. Journal of Clinical Pharmacology 22, 281 289.
35. Ferrario CM. (2006). Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. Journal of Renin-Angiotensin-Aldosterone System 7, 3 14.
36. Ferro C.J., Spratt J.C, Haynes W.G. et al 1998). Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 97, 2323 2330.
37. Fiebeler A., Muller D.N., Shagdarsuren E. et al 2007). Aldosterone, mineralocorticoid receptors, and vascular inflammation. Current Opinion in Nephrology and Hypertension 16, 134 142.
38. Fuller P.J., Young M.J. (2005). Mechanisms of mineralocorticoid action. Hypertension 46, 1227 1235.
39. Garthwaite S.M., McMahon E.G. (2004). The evolution of aldosterone antagonists. Molecular and Cellular Endocrinology 217, 27 31.
40. Gavras H., Faxon D.P., Berkoben J. et al 1978). Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 58, 770 776.
41. Go A.S., Chertow G.M., Fan D. et al 2004). Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine 351, 1296 1305.
42. Goldblatt H., Lynch J., Hanzal R.F et al 1934). Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. The Journal of Experimental Medicine 59, 347 379.
43. Gross F, Lazar J., Orth H. (1972). Inhibition of the renin- angiotensinogen reaction by pepstatin. Science 175, 656.
44. Heart Outcomes Prevention Evaluation Study Investigators (2000). Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253 259.
45. Hollenberg N.K. (2009). Direct renin inhibition and the kidney. Nature Reviews Nephrology. Advance online publication.
46. Hou F.F., Zhang X., Zhang G.H. et al 2006). Efficacy and safety of benazepril for advanced chronic renal insufficiency. New England Journal of Medicine 354, 131 140.
47. Hsueh W.A. Baxter J.D. (1991). Human prorenin. Hypertension 17, 469 477.
48. Ibrahim H.N., Hostetter T.H. (2003). Aldosterone in renal disease. Current Opinion in Nephrology and Hypertension 12, 159 164.
49. Jafar T.H., Schmid C.H., Landa M. et al 2001). Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of Internal Medicine 135, 73 87.
50. Jaffe I.Z., Mendelsohn M.E. (2005). Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circulation Research 96, 643 650.
51. Jain G., Campbell R.C., Warnock D.G. (2009). Mineralocorticoid receptor blockers and chronic kidney disease. Clinical Journal of the American Society of Nephrology 4, 1685 1691.
52. Jensen J.S., Borch-Johnsen K., Jensen G. et al 1995). Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clinical Science (London) 88, 629 633.
53. Kagawa CM., Cella J.A., Van Arman C.G. (1957). Action of new steroids in blocking effects of aldosterone and desoxycorticos-terone on salt. Science 126, 1015 1016.
54. Karlberg B.E., Fyhrquist F., Gronhagen-Riska C. et al 1984). Enalapril and lisinopril in renovascular hypertension-antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report. Scandinavian Journal of Urology and Nephrology 79, 103 106.
55. Khalil M.E., Basher A.W., Brown E.J. et al 2001). A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. Journal of the American College of Cardiology 37, 1757 1764.
56. Klutchko S., Blankley C.J., Fleming R.W. et al 1986). Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types. Journal of Medicinal Chemistry 29, 1953 1961.
57. Kunz R., Wolbers M., Glass T. et al 2008). The COOPERATE trial: a letter of concern. Lancet 371, 1575 1576.
58. Kurtz T.W., Klein U. (2009). Next generation multifunctional angiotensin receptor blockers. Hypertension Research 32, 826 834.
59. Lewis E.J., Hunsicker L.G., Bain R.P. et al. (1993). The Collaborative Study Group. The Effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New England Journal of Medicine 329, 1456 1462.
60. Lewis E.J., Hunsicker L.G., Clarke W.R. et al 2001). Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 345, 851 860.
61. Mann J.F, Gerstein H.C., Pogue J. et al 2001). Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of Internal Medicine 134, 629 636.
62. Mann J.F, Schmieder R.E., McQueen M. et al 2008). Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547 553.
63. McMurray J.J., Pitt B., Latini R. et al 2008). Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation: Heart Failure 1, 17 24.
64. Menard J. (2004). The 45-year story of the development of an antialdosterone more specific than spironolactone. Molecular and Cellular Endocrinology 217, 45 52.
65. Messerli F.H. (2009). The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. Journal of the American College of Cardiology 53, 468 470.
66. Millar J.A., Derkx F.H., McLean K. et al 1982). Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. British Journal of Clinical Pharmacology 14, 347 355.
67. Mogi M., Iwai M., Horiuchi M. (2007). Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arteriosclerosis, Thrombosis, and Vascular Biology 27, 2532 2539.
68. Nakao N., Yoshimura A., Morita H. et al 2003). Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361, 117 124. (Pubitemid 36092015)
69. Nguyen G., Delarue F, Berrou J. et al 1996). Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney International 50, 1897 1903.
70. Nguyen G., Delarue F, Burckle C. et al 2002). Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. Journal of Clinical Investment 109, 1417 1427.
71. Niarchos A.P., Pickering T.G., Wallace J.M. et al 1980). Hemodynamic effects of the converting enzyme inhibitor teprotide in normal-and high-renin hypertension. Clinical Pharmacology and Therapeutics 28, 592 601.
72. Nishiyama A., Matsusaka T, Miyata T. (2009). Angiotensin II type 1A receptor deficiency and longevity. Nephrology Dialysis Transplantation 24, 3280 3281.
73. O'Rourke M.F. (1992). Frederick Akbar Mahomed. Hypertension 19, 212 217.
74. Onuigbo M.A. (2009a). Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution. Nephron Clinical Practice 113, c63 c69, discussion c70.
75. Onuigbo M.A. (2009b). Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET - a call for more circumspection. QJM 102, 155 167.
76. Page I.H., Mc C.J., Schwarz H. et al 1957). Pharmacologic aspects of synthetic angiotonin. Circulation Research 5, 552 555.
77. Pandey R., Quan W.Y., Hong F. et al 2009). Vaccine for hypertension: modulating the renin-angiotensin system. International Journal of Cardiology 134, 160 168.
78. Parving H.H., Persson F., Lewis J.B. et al 2008). Aliskiren combined with losartan in type 2 diabetes and nephropathy. New England Journal of Medicine 358, 2433 2446.
79. Phillips M.I., Schmidt-Ott K.M. (1999). The discovery of renin 100 years ago. News in Physiological Science 14, 271 274.
80. Ravid M., Savin H., Jutrin I., Bental T., Katz B. Lishner M. (1993). Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Annals of Internal Medicine 118, 577 581.
81. Richer C., Doussau M.P., Giudicelli J.F. (1986). Perindopril, a new converting enzyme inhibitor: systemic and regional hemodynamics and sympathoinhibitory effects in spontaneously hypertensive rats. Journal of Cardiovascular Pharmacology 8, 346 357. (Pubitemid 16108740)
82. Rossing K., Schjoedt K.J., Jensen B.R. et al 2005). Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney International 68, 1190 1198.
83. Rubin B., Antonaccio M.J., Horovitz Z.P. (1978). Captopril (SQ 14,225) (D-3-mercapto-2-methylpropranoyl-L-proline): a novel orally active inhibitor of angiotensin-converting enzyme and antihyper-tensive agent. Progress in Cardiovascular Diseases 21, 183 194. (Pubitemid 9068239)
84. Ruggenenti P., Perna A., Gherardi G. et al 1999). Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354, 359 364.
85. Sano T., Kawamura T., Matsumae H. et al 1994). Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 17, 420 424.
86. Santos R.A., Ferreira A.J. (2007). Angiotensin-(1-7) and the renin-angiotensin system. Current Opinion in Nephrology and Hypertension 16, 122 128.
87. Schefe J.H., Menk M., Reinemund J. et al 2006). A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circulation Research 99, 1355 1366.
88. Schiffrin E.L. (2006). Effects of aldosterone on the vasculature. Hypertension 47, 312 318.
89. Skeggs L.T., Jr., Kahn J.R., Lentz K. et al 1957). The preparation, purification, and amino acid sequence of a polypeptide renin substrate. Journal of Experimental Medicine 106, 439 453.
90. Skott O., Uhrenholt T.R., Schjerning J. et al 2006). Rapid actions of aldosterone in vascular health and disease-friend or foe? Pharmacology and Therapeutics 111, 495 507.
91. Staessen J.A., Li Y, Richart T. (2006). Oral renin inhibitors. Lancet 368, 1449 1456.
92. Steckelings U.M., Rompe F., Kaschina E. et al 2009). The past, present and future of angiotensin II type 2 receptor stimulation. Journal of Renin-Angiotensin-Aldosterone System 11, 67 73.
93. Strippoli G.F., Craig J.C., Schena F.P. (2004). The number, quality, and coverage of randomized controlled trials in nephrology. Journal of the American Society of Nephrology 15, 411 419.
94. Struthers A., Krum H., Williams G.H. (2008). A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clinical Cardiology 31, 153 158.
95. Tait S.A., Tait J.F. (1998). The correspondence of S.A.S. Simpson and J.F. Tait with T. Reichstein during their collaborative work on the isolation and elucidation of the structure of electrocortin (later aldosterone). Steroids 63, 440 453.
96. Takeda Y., Miyamori I., Inaba S. et al 1997). Vascular aldosterone in genetically hypertensive rats. Hypertension 29, 45 48.
97. Takeda Y., Yoneda T., Demura M. et al. (2000). Cardiac aldosterone production in genetically hypertensive rats. Hypertension 36, 495 500.
98. The Editors of The Lancet 2009). Retraction-Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 374, 1226.
99. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) 1997). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349, 1857 1863.
100. Theodoratou D., Maniadakis N., Fragoulakis V. et al 2009). Analysis of published economic evaluations of angiotensin receptor blockers. The Hellenic Journal of Cardiology 50, 105 118.
101. Tigerstedt R., Bergman P. (1898). Niere und Kreislauf. Archives in Physiology 8, 223 271.
102. Trevisan R., Tiengo A. (1995). Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. American Journal of Hypertension 8, 876 883.
103. Wheatley K., Ives N., Gray R. et al 2009). Revascularization versus medical therapy for renal-artery stenosis. New England Journal of Medicine 361, 1953 1962.
104. Wilson D.M., Luetscher J.A. (1990). Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. New England Journal of Medicine 323, 1101 1106.
105. Wood J.M., Maibaum J., Rahuel J. et al 2003). Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochemical and Biophysical Research Communications 308, 698 705.
106. Wright J.T., Jr., Bakris G., Greene T. et al 2002). Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288, 2421 2431.
107. Xiang J.Z., Linz W., Becker H. et al 1985). Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart. European Journal of Pharmacology 113, 215 223.
108. Yusuf S., Sleight P., Pogue J. et al 2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New England Journal of Medicine 342, 145 153.